Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422)
China
· Delayed Price · Currency is CNY 32.30
-1.57 (-4.64%)
Oct 11, 2024, 3:04 PM CST
Sichuan Kelun Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 2,852 | 2,456 | 1,705 | 1,103 | 829.39 | 937.86 | Upgrade
|
| Depreciation & Amortization | 1,226 | 1,233 | 1,185 | 1,218 | 1,155 | 1,070 | Upgrade
|
| Other Amortization | 37.47 | 32.66 | 13.11 | 7.55 | 5.93 | 4.67 | Upgrade
|
| Loss (Gain) From Sale of Assets | -3.39 | -2.63 | -5.4 | 7.94 | 21.45 | 9.49 | Upgrade
|
| Asset Writedown & Restructuring Costs | 58.62 | 58.62 | 1.93 | 5.26 | 0.34 | 6.7 | Upgrade
|
| Loss (Gain) From Sale of Investments | -415.28 | -373.58 | -244.68 | -220.34 | -94.82 | -174.05 | Upgrade
|
| Stock-Based Compensation | - | - | - | - | - | 5.65 | Upgrade
|
| Provision & Write-off of Bad Debts | 37.37 | 36.21 | 47.75 | 36.82 | 52.47 | 74.82 | Upgrade
|
| Other Operating Activities | 772.44 | 647.31 | 535.93 | 357.07 | 793.64 | 834.29 | Upgrade
|
| Change in Accounts Receivable | -268.94 | 1,088 | -905.52 | 625.71 | 67.73 | -764.39 | Upgrade
|
| Change in Inventory | -97.74 | -645.26 | 168.36 | 107.42 | -129.56 | -452.77 | Upgrade
|
| Change in Accounts Payable | -205.96 | 313.96 | 579.36 | -365.49 | -405.45 | 734.36 | Upgrade
|
| Change in Other Net Operating Assets | 202.53 | 218.55 | 71.31 | - | - | - | Upgrade
|
| Operating Cash Flow | 4,454 | 5,337 | 3,127 | 2,847 | 2,219 | 2,217 | Upgrade
|
| Operating Cash Flow Growth | -15.39% | 70.68% | 9.83% | 28.28% | 0.12% | -24.95% | Upgrade
|
| Capital Expenditures | -2,000 | -1,769 | -896.7 | -990.56 | -1,231 | -1,331 | Upgrade
|
| Sale of Property, Plant & Equipment | -4.26 | 1.28 | 12.72 | 7.98 | 6.08 | 34.01 | Upgrade
|
| Divestitures | 48.47 | 80.79 | 5.93 | -30.14 | 623.5 | 1.19 | Upgrade
|
| Investment in Securities | 292.07 | -1,808 | -89.08 | -578.99 | -381.64 | -318.55 | Upgrade
|
| Other Investing Activities | 154.33 | 124.55 | 110.03 | 61.92 | 77.66 | 255.05 | Upgrade
|
| Investing Cash Flow | -1,509 | -3,370 | -857.1 | -1,530 | -905.28 | -1,359 | Upgrade
|
| Long-Term Debt Issued | - | 4,028 | 10,358 | 9,004 | 11,614 | 5,814 | Upgrade
|
| Long-Term Debt Repaid | - | -7,319 | -10,641 | -9,445 | -10,988 | -5,342 | Upgrade
|
| Net Debt Issued (Repaid) | -786.89 | -3,291 | -283.2 | -441.32 | 625.8 | 472.03 | Upgrade
|
| Issuance of Common Stock | - | - | - | 30 | - | 273.37 | Upgrade
|
| Repurchase of Common Stock | -1,388 | - | -151.7 | -226.15 | -135.11 | -272.72 | Upgrade
|
| Common Dividends Paid | -1,431 | -1,127 | -1,033 | -995.9 | -1,132 | -849.1 | Upgrade
|
| Other Financing Activities | 2,897 | 2,359 | 1,061 | 362.61 | -80.79 | -91.58 | Upgrade
|
| Financing Cash Flow | -708.11 | -2,059 | -407.26 | -1,271 | -722.11 | -467.99 | Upgrade
|
| Foreign Exchange Rate Adjustments | -7.02 | 5.19 | 7.93 | -8.27 | -28.21 | 2.22 | Upgrade
|
| Net Cash Flow | 2,229 | -86.83 | 1,871 | 38.31 | 563.79 | 391.63 | Upgrade
|
| Free Cash Flow | 2,454 | 3,568 | 2,230 | 1,857 | 988.5 | 885.7 | Upgrade
|
| Free Cash Flow Growth | -42.58% | 59.98% | 20.13% | 87.82% | 11.61% | -45.47% | Upgrade
|
| Free Cash Flow Margin | 10.91% | 16.63% | 11.71% | 10.75% | 6.00% | 5.02% | Upgrade
|
| Free Cash Flow Per Share | 1.58 | 2.31 | 1.50 | 1.31 | 0.69 | 0.62 | Upgrade
|
| Cash Income Tax Paid | 2,734 | 2,576 | 2,081 | 1,876 | 1,537 | 1,739 | Upgrade
|
| Levered Free Cash Flow | -185.92 | 1,916 | 1,235 | 1,803 | 237.91 | -205.22 | Upgrade
|
| Unlevered Free Cash Flow | -47.68 | 2,142 | 1,532 | 2,127 | 584.7 | 160.3 | Upgrade
|
| Change in Net Working Capital | 2,244 | -300.55 | 181.68 | -964.33 | 108 | 648.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.